FibroBiologics Expands Fibroblast IP Portfolio to 170 Issued Patents

For CDMOs and cell therapy manufacturers evaluating fibroblast-based programs, FibroBiologics has materially raised the IP barrier to entry: the company now holds 170 issued patents and more than 325 issued and pending worldwide, covering not only therapeutic indications but the manufacturing methods used to produce fibroblast therapies.

The portfolio has grown from 124 issued patents as of 31 December 2025, with 2026 grants spanning U.S. patents in wound healing, type 1 diabetes, osteoporosis, cachexia, and degenerative disc disease, alongside European patents covering methods of enhancing fibroblast therapeutic activity and fibroblast-mediated delivery of tumor inhibitory agents. More than 150 applications remain pending across 50-plus patent families.

The manufacturing coverage is where the portfolio carries the sharpest operational relevance. Protected methods include preparation of three-dimensional fibroblast spheroids, automated generation of core-shell spheroids, gene modification, surface marker modification for tissue-directed delivery, fibroblast conditioned media, organoids, and oral delivery systems. Recent filings extend into injectable thymus organoids and three-dimensional cell aggregates engineered to produce and secrete therapeutic peptides. Any CDMO or platform technology provider working in adjacent fibroblast manufacturing space will need to map their process IP against this coverage before advancing development agreements.

Therapeutic indications protected span degenerative disc disease, cartilage and joint repair, multiple sclerosis, psoriasis, lupus, and cancer, among others, with additional patent families addressing immune function, thymus and spleen regeneration, and human longevity applications. The breadth across clinical pathways is consistent with a platform strategy designed to support multiple partnering structures from a single cell type.

FibroBiologics was founded in 2021; the pace of issuance since then reflects a sustained filing strategy rather than a single prosecution cycle, which bears on how partners and licensees should assess the durability of rights being offered.

The next measurable checkpoint is the resolution of the 150-plus pending applications, the outcome of which will determine whether manufacturing method coverage extends further into automated bioprocessing and novel delivery formats.

Source: FibroBiologics, Inc. via PR Newswire, 12 November 2026.